Interferon alfa-2b

Base Information

• Chemical Name: Interferon alfa-2b
• CAS No.: 98530-12-2
• Molecular Formula: C16H17Cl3I2N3NaO5S
• Molecular Weight: 19269.10
• Mol file: 98530-12-2.mol

Synonyms:11:PN: WO0009143 SEQID: 24 claimed protein; 7: PN: WO0006735 FIGURE: 5 claimedprotein; Cibian; INF-a2; Interferon alfa-2b; Interferon a-2b; Interferon a2b (human leukocyte clone Hif-SN206 protein moietyreduced); Interferon-a2b (plasmid pMON20442); Interferon-a2b (plasmid pMON30422); Interferon-a2b (plasmid pMON30426); Intron(Interferon a2b);Intron A; Intron A (Interferon a2b); PN: WO9951638 SEQID: 19 claimed protein; Realdiron; Sch 30500;Viraferon; YM 14090; aAD-Interferon (human clone 36422.pep)

Chemical Property of Interferon alfa-2b

Chemical Property:

• PSA: 112.94000
• LogP: 6.36840

Purity/Quality:

99%, ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Indications: Interferon alfa-2b (Intron A) is a recombinant DNA product derived from the interferon alfa-2b gene of human white blood cells. Its mechanism of antitumor action involves binding to a plasma membrane receptor but is otherwise poorly understood. Its serum half-life is 2 to 3 hours after parenteral administration.
• Clinical Use: Interferon alfa-2b is useful in the treatment of a rare form of chronic leukemia, hairy cell leukemia, in which it produces remissions in 60 to 80% of patients. However, it has minimal antitumor activity in most human cancers.Remissions lasting a few months have been observed in 10 to 20% of patients with lymphomas, multiple myeloma, melanoma, renal cell carcinoma, and ovarian carcinoma.
• Drug interactions: Potentially hazardous interactions with other drugs Aminophylline and theophylline: metabolism of aminophylline and theophylline reduced, consider reducing dose of aminophylline and theophylline. Antivirals: increased risk of peripheral neuropathy with telbivudine. Immunosuppressants, e.g. ciclosporin, tacrolimus, sirolimus may have an antagonistic effect. Administration of interferon in combination with other chemotherapeutic agents, e.g. cytarabine, cyclophosphamide, doxorubicin may lead to increased risk of severe toxicity.